Jonathan Lanfear Net Worth

Jonathan Lanfear biography

Jonathan Lanfear is Director of the Company. Mr. Lanfear is the Vice President and Global Head of Oncology & Neuroscience Business Development at Takeda Pharmaceuticals International. Prior to joining Takeda in December 2011, Mr. Lanfear spent approximately 8 years at Pfizer Inc. as a Senior Director and Transactions Lead in the Worldwide Business Development, Strategy, & Innovation group. Mr. Lanfear previously served in a biotechnology equity research position at AG Edwards/Wachovia and in a business development position at Searle/Pharmacia where he worked on several significant licensing transactions prior to the company’s acquisition. Mr. Lanfear holds a B.S. in Chemical Engineering and a Master’s degree in Bioengineering, both from the University of Michigan (Ann Arbor), and an MBA from Washington University (St. Louis). Mr. Lanfear currently serves on the board of directors of Aquinnah Pharmaceuticals, a privately-held neurodegeneration-focused company. Our Board has concluded that Mr. Lanfear should serve as a director of the Company based on Mr. Lanfear’s industry perspective and experience.

How old is Jonathan Lanfear?

Jonathan Lanfear is 51, he's been the Independent Director of Molecular Templates Inc since 2018. There are 8 older and 11 younger executives at Molecular Templates Inc. The oldest executive at Molecular Templates Inc is David Hoffmann, 75, who is the Independent Director.

What's Jonathan Lanfear's mailing address?

Jonathan's mailing address filed with the SEC is C/O MOLECULAR TEMPLATES, INC., 9301 AMBERGLEN BLVD., SUITE 100, AUSTIN, TX, 78729.

Insiders trading at Molecular Templates Inc

Over the last 7 years, insiders at Molecular Templates Inc have traded over 22,993,582$ worth of Molecular Templates Inc stock and bought 14,744,530 units worth 82,519,716$ . The most active insiders traders include Target N Vbb Biotech Ag Bio...、David Hirsch、Capital Partners Iii, Llc L.... On average, Molecular Templates Inc executives and independent directors trade stock every 47 days with the average trade being worth of 532,718$. The most recent stock trade was executed by Target N Vbb Biotech Ag Bio... on 2 April 2024, trading 250,000 units of MTEM stock currently worth 587,500$.

What does Molecular Templates Inc do?

molecular templates (mtem) is a clinical-stage biopharmaceutical company targeting a variety of cancers through development of its innovative proprietary engineered toxin body (etb) platform. mtem’s first immunotoxin, mt-3724, is in clinical development for non-hodgkin’s lymphoma. pipeline products for additional oncology targets are being advanced toward clinical development. for more information, please visit mtem’s website at www.mtem.com.

Molecular Templates Inc executives and stock owners

Molecular Templates Inc executives and other stock owners filed with the SEC include:

• Eric Poma,
  Chief Executive Officer, Chief Scientific Officer, Director
• Roger Waltzman,
  Chief Medical Officer
• Jason Kim,
  President, Chief Operating Officer
• Adam Cutler,
  Chief Financial Officer, Treasurer, Secretary
• Dr. Eric E. Poma,
  CEO, Chief Scientific Officer & Director
• Dr. Roger J. Waltzman M.B.A., M.D.,
  Chief Medical Officer
• Jason S Kim,
  Pres & COO
• Dr. Roger J. Waltzman,
  Chief Medical Officer
• Corazon Sanders,
  Independent Director
• Harold Selick,
  Chairman of the Board
• Kevin Lalande,
  Independent Director
• David Hirsch,
  Independent Director
• David Hoffmann,
  Independent Director
• Scott Morenstein,
  Independent Director
• Jonathan Lanfear,
  Independent Director
• Michael Dowd,
  Sr. VP of Project & Alliance Management
• Megan C. Filoon,
  Gen. Counsel & Sec.
• Dr. Nenad Sarapa M.D., M.S.,
  Sr. VP of Clinical Devel.
• Dr. Jen-Sing Liu Ph.D.,
  Exec. VP of Manufacturing
• Dr. Erin Willert Ph.D.,
  Exec. VP of R&D
• Dr. Jack Higgins Ph.D.,
  Exec. VP of Operations & Head of Manufacturing
• Kurt Elster,
  Exec. VP of Corp. Devel.
• Sean McLennan,
  Sr. VP of Fin., Controller, Interim Principal Accounting Officer, Interim CFO & Treasurer
• Associates, L.L.C.Morenstei...,
  
• Target N Vbb Biotech Ag Bio...,
  
• Dave Hoffmann,
  Director
• Capital Partners Iii, Llc L...,
  
• Scott Dcdk Associates, L.L....,
  
• Management Services, Llc Cu...,
  
• Sean Mc Lennan,
  See remarks
• Management Services, Llc Cu...,
  
• Gabriela Gruia,
  Director
• Maurizio Voi,
  Chief Medical Officer